EDSA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	5 021.00
Average Volume	12 670.00
Market Cap	13.67M
EPS	$-0.600 ( 2024-02-09 )
Next earnings date	( $-0.690 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.210
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Nijhawan Pardeep	Buy	3 253	Common Shares
2024-03-25	Nijhawan Pardeep	Buy	5 000	Common Shares
2024-03-01	Nijhawan Pardeep	Buy	2 765	Common Shares
2024-02-01	Nijhawan Pardeep	Buy	2 978	Common Shares
2024-01-08	Nijhawan Pardeep	Buy	2 908	Common Shares

INSIDER POWER
76.21
Last 96 transactions
Buy: 2 356 026 \| Sell: 309 119

Edesa Biotech Inc Correlation

10 Most Positive Correlations
CTRM	0.95
FSEA	0.947
INPX	0.946
SSBK	0.943
XOS	0.941
NUWE	0.937
SBFG	0.935
FFWM	0.934
SGMO	0.934
MDRX	0.933

10 Most Negative Correlations
RMRM	-0.927
MCAA	-0.925
QQC	-0.925
PLPC	-0.92
BNIX	-0.92
MSDA	-0.915
DSEY	-0.913
ZING	-0.912
ARNA	-0.912
VMGA	-0.911

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Edesa Biotech Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-183 471 (0.00 %)
EPS:	$-0.420

Q1	2024
Revenue:	$0
Gross Profit:	$-45 031.00 (0.00 %)
EPS:	$-0.540

Q4	2023
Revenue:	$-1.12M
Gross Profit:	$-1.16M (104.11 %)
EPS:	$-0.0799

Q3	2023
Revenue:	$0
Gross Profit:	$-82 999.00 (0.00 %)
EPS:	$-0.0968

Financial Reports:

No articles found.

Edesa Biotech Inc

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.